Technology and advanced analytics in clinical research is an extremely broad topic and its development is accelerating. Within the clinical research environment, late-phase research (Phases IIIb, IV, observational research) represents a growing sector. Across the globe, the long-term safety and side-effects of new medicines is a priority, and regulatory agencies are increasingly requiring real-world clinical evidence (RWE) from patients to substantiate the data and to demonstrate long-term value. Lorna Graham, deMauri Mackie, William L. Slone and Michael Murphy of World Wide Clinical Trials explain why this is the case.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/05/Pushing-new-boundaries_technology-and-advanced.pdf” width=”100%” height=”900px” style=”border:0;”]